Compare DexCom, Inc. (DXCM) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs VanEck Australian Floating Rate ETF — how do they compare? DexCom, Inc. trades at $90.55 (market cap $34.26B), while VanEck Australian Floating Rate ETF trades at $50.94. The key difference: DexCom, Inc. is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | FLOT | |
|---|---|---|
Market Cap | $34.26B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.80 | $51.09 |
52-Week Low | $54.84 | $50.72 |
Enterprise Value | $33.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FLOT trades at $50.93, up 0.02% on the day, with a bearish technical signal from moving averages and oscillators neutral. Recent dividends include $0.18 paid on June 4, 2026, and $0.17 scheduled for July 7, 2026. The stock's support and resistance levels are consolidated around $51, indicating limited near-term price movement potential.
Outlook remains cautious due to bearish technical indicators and sensitivity to Federal Reserve rate decisions. Opportunities exist if rate hikes materialize, boosting yield appeal, but risks include inflation persistence and geopolitical tensions affecting Treasury yields. Investors should weigh income stability against interest rate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
